BlackRock Edges Past Pfizer Into the S&P 500's No. 77 Slot
BlackRock has moved ahead of Pfizer to claim the No. 77 place among S&P 500 companies by market value, a swap that reflects how differently asset managers and big pharma have been priced.
BlackRock Inc (BLK) has overtaken Pfizer Inc (PFE) for the No. 77 spot in the S&P 500 ranked by market capitalization, according to The Online Investor, with BLK last trading at 1,065.60 and PFE at 27.72 as of Sept. 14, 2026.
BlackRock Inc (NYSE: BLK) has moved up one rung in the S&P 500's market-capitalization pecking order, displacing Pfizer Inc (NYSE: PFE) from the No. 77 position, according to a review of index components published by The Online Investor and carried by Nasdaq Markets.
Rank changes of a single place inside the S&P 500 rarely move a share price on their own. They matter because they are a scoreboard: the index is weighted by market value, so a company's position is a running tally of how much capital the market has assigned to it relative to every other constituent. When two names swap places, one has been bid up, the other marked down, or both.
What the tape looked like on the day of the swap
The crossover was recorded in a market that finished lower across the board. As of the last trade on Monday, Sept. 14, 2026 at 20:00 GMT, the S&P 500 tracker SPY closed at $760.88, down 0.45% from a prior close of $764.29, with a day range of $757.93 to $763.52. The Nasdaq 100 proxy QQQ was weaker still at $709.18, off 0.80%, while the Dow 30 vehicle DIA slipped 0.25% to $524.49.
BlackRock itself did not lead the move higher on the session. Its shares last changed hands at 1,065.60, down 1.30% from a previous close of 1,079.65, having traded between 1,057.72 and 1,080.02. Pfizer was unchanged on the day at 27.72, having touched 28.19 at the high and 27.68 at the low.
That combination is worth pausing on. A rank change is a cumulative fact, not a one-day one. BlackRock overtook Pfizer even as BlackRock fell and Pfizer held flat, which tells you the gap had already closed before Monday's session and that the arithmetic simply tipped over at some point in the recent past. Rank tables reflect where the two companies' valuations stand after weeks and months of divergence, not where they moved in a single afternoon.
Two very different businesses, priced differently
BlackRock and Pfizer are unusual neighbours in a valuation table. One collects fees on assets it manages for other people; the other discovers, manufactures and sells medicines. Their earnings streams respond to almost nothing in common.
An asset manager's market value is closely tied to the level of global markets. When equity and bond indices rise, assets under management rise with them, fee revenue follows, and the shares tend to re-rate. The cash-flow profile is annuity-like: fees accrue on balances rather than on discrete events. That is a structurally different risk than the one a large pharmaceutical carries.
Big pharma valuations turn on the pipeline and the patent clock. Revenue from a blockbuster is finite by design, and the market prices in both the cliff at the end of exclusivity and the probability that the next candidates in development replace it. Trial readouts, regulatory decisions and pricing policy can reset a drugmaker's value in a single morning in a way that a fee-based business seldom experiences.
Put those two engines side by side and it becomes easier to see why the relative ranking of the two names can drift. The market has, on the evidence of this swap, been willing to pay more in aggregate for BlackRock's fee base than for Pfizer's product portfolio and pipeline.
Why index rank is more than trivia
Put those two engines side by side and it becomes easier to see why the relative ranking of the two names can drift.
The S&P 500 is capitalization-weighted, and an enormous pool of passive money tracks it. Every index fund and ETF benchmarked to the S&P 500 holds its constituents in proportion to their float-adjusted market value. A company that grows its market cap relative to peers therefore absorbs a marginally larger share of every dollar that flows into index products, and a company that shrinks relative to peers gives some of that share back.
At the No. 77 position the weights involved are small, and a single-place move does not force meaningful rebalancing. But the direction of travel matters over time. A name climbing steadily through the ranks is one whose weight in passive portfolios is quietly increasing; a name sliding is the reverse. For BlackRock, a company whose own iShares franchise is one of the largest beneficiaries of index investing, there is a certain symmetry in the mechanic.
Rank is also a useful cross-sector lens for investors who otherwise never compare a bank-adjacent business with a drugmaker. It strips away sector narrative and leaves a single number: what the market says each enterprise is worth.
What to watch from here
Three things determine whether this swap sticks.
- The level of global markets. BlackRock's assets under management, and therefore its fee revenue, rise and fall with market values. A sustained drawdown in equities and credit works directly against the company's valuation — and Monday's broad decline, with all three major benchmarks lower, is the kind of session that does so at the margin.
- Pfizer's pipeline news flow. A single positive late-stage readout or regulatory clearance can re-rate a large pharmaceutical quickly. Pfizer held flat on the day while the wider index fell, which is the sort of defensive behaviour investors often seek from healthcare when risk appetite thins.
- Flows into passive products. Continued growth in index investing supports the revenue base of the largest ETF sponsors, BlackRock among them, even as it compresses fees.
Neither company's business changed because a table was reordered. But for anyone tracking how the market's judgment on financials versus healthcare is evolving, the No. 77 slot is a small, precise data point — and it now belongs to BlackRock.
Key facts
- Rank change: BlackRock takes the #77 S&P 500 market-cap spot from Pfizer
- BLK last price: 1,065.60, -1.30% (last trade Sept. 14, 2026, 20:00 GMT)
- PFE last price: 27.72, +0.00% (last trade Sept. 14, 2026, 20:00 GMT)
- Market backdrop: S&P 500 tracker SPY closed at $760.88, down 0.45%
Frequently asked questions
What exactly changed between BlackRock and Pfizer?
In a ranking of S&P 500 companies ordered by largest market capitalization, BlackRock Inc took over the No. 77 position from Pfizer Inc, according to The Online Investor. It is a relative valuation change: the market's aggregate assessment of BlackRock's worth moved above Pfizer's, reordering the two names in the index table.
Does a market-cap rank change affect the share price?
Not directly. A rank change is a consequence of price moves, not a cause of them. Because the S&P 500 is capitalization-weighted, a rising market value does gradually increase a company's weight in index funds that track the benchmark, but a single-place move near the No. 77 position is too small to force meaningful rebalancing by passive managers.
Where did the two stocks last trade?
As of the last trade on Sept. 14, 2026 at 20:00 GMT, BlackRock stood at 1,065.60, down 1.30% from a previous close of 1,079.65, with a day range of 1,057.72 to 1,080.02. Pfizer was unchanged at 27.72, having traded between 27.68 and 28.19 during the session.
How did the broader market perform that day?
All three major US benchmarks closed lower. The S&P 500 tracker SPY ended at $760.88, down 0.45% from $764.29. The Nasdaq 100 proxy QQQ fell 0.80% to $709.18, and the Dow 30 vehicle DIA slipped 0.25% to $524.49. It was a broadly risk-off session rather than a rally in financials.
Why are an asset manager and a drugmaker valued so differently?
Their cash flows respond to different forces. An asset manager earns fees on assets under management, so its revenue tracks the level of global markets and behaves like an annuity. A large pharmaceutical depends on patent-protected products with finite lives, so its value hinges on pipeline outcomes, regulatory decisions and pricing policy.
What is market capitalization and why do investors track it?
Market capitalization is a company's share price multiplied by its outstanding shares — the market's total price tag on the business. Investors track it because it determines index weighting, shapes how much passive money a stock receives, and allows direct comparison of enterprise value across completely unrelated industries.
Sources
- Blackrock Moves Up In Market Cap Rank, Passing Pfizer — Nasdaq Markets
Photo: https://kaboompics.com/ · Pexels Licence — source
